

## **NC DMA Pharmacy Request for Prior Approval - Triptans**



Recipient Information	DMA-0023
1. Recipient Last Name:	2. First Name:
3. Recipient ID # 4. Reci	pient Date of Birth: 5. Recipient Gender:
Payer Information	
6. Is this a Medicaid or Health Choice Request?	Medicaid: Health Choice:
Prescriber Information	
7. Prescribing Provider #:	NPI: or Atypical:
8. Prescriber DEA #:	
Requester Contact Information Name:	Phone #:Ext:
Drug Information	
9a. Drug Name:	9b. Is this request for a Non-Preferred Drug?
10. Strength: 11. Quantity Per 30 Days:	
12. Length of Therapy (in days): up to 30 60 90 120 180 365 Other:	
Clinical Information	
Request for Non-Preferred Drug:	
1. Failed two preferred drug(s). List preferred drugs failed	ed:
1a. Allergic Reaction 1b. Drug-to-drug interaction. Please describe reaction:	
2. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:	
3. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s).	
Please provider clnicial information:	
4. Age specific indications. Please give patient age and explain:	
5. Unique clinical indication supported by FDA approval	or peer reviewed literature. Please explain and provide a general reference:
6. Unacceptable clinical risk associated with therapeutic change. Please explain:	
Request for Exceeding Quantity Limit (Check all that apply.)	
7. Does the patient have a diagnosis of migraine or cluster headache?	
8. Does the patient have more than 6 moderate or severe headache days per month?  Yes No	
9. Does the patient have a history of NSAID therapy in the past year?	
10. Does the patient have a contraindication or allergy to NSAID therapy? Yes No	
11. Is the patient currently receiving therapy with a migrain	
	n adverse reaction with preventative medications?
Please list:	
	0 day trial of preventative medications at the maximum tolerated dose?
14. Has the patient been diagnosed with Ischemic Heart Dis Cerebrovascular Disease, Ischemic Bowel Disease, or Hemip	
15. Has the patient received an MAO Inhibitor in the past 2	
16. Has the patient received an ergot medication in the past 2	
17. Does the patient have uncontrolled hypertension or basilar migraine? Yes No	
18. Has the prescriber reviewed the DMA evidenced-based recommendations on the treatment of migraine? Yes No	
I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or	
concealment of material fact may subject me to civial or criminal liability.	
Signature of Prescriber:	Date:
*Prescriber signature	mandatory

Fax this form to CSC at: (855) 710-1964 Pharmacy PA Call Center: (866) 246-8505